Vistagen Therapeutics Inc Forecasted to Earn Q3 2019 Earnings of ($0.30) Per Share (VTGN)

Share on StockTwits

Vistagen Therapeutics Inc (NASDAQ:VTGN) – Stock analysts at Oppenheimer reduced their Q3 2019 earnings per share estimates for Vistagen Therapeutics in a report issued on Sunday, November 4th. Oppenheimer analyst J. Olson now expects that the company will post earnings of ($0.30) per share for the quarter, down from their prior estimate of ($0.19). Oppenheimer has a “Buy” rating and a $6.00 price objective on the stock. Oppenheimer also issued estimates for Vistagen Therapeutics’ Q4 2019 earnings at ($0.30) EPS, FY2019 earnings at ($1.10) EPS, FY2020 earnings at ($1.48) EPS, FY2021 earnings at ($1.76) EPS, FY2022 earnings at ($2.02) EPS and FY2023 earnings at ($2.68) EPS.

Vistagen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings data on Monday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.13).

A number of other research firms have also recently commented on VTGN. Maxim Group set a $6.00 target price on shares of Vistagen Therapeutics and gave the company a “buy” rating in a research report on Thursday, October 25th. Zacks Investment Research lowered shares of Vistagen Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 25th. Finally, ValuEngine upgraded shares of Vistagen Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $8.30.

Shares of VTGN opened at $2.10 on Wednesday. Vistagen Therapeutics has a fifty-two week low of $0.69 and a fifty-two week high of $2.65. The company has a market capitalization of $65.22 million, a PE ratio of -1.89 and a beta of -1.53.

Vistagen Therapeutics Company Profile

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Featured Story: Cash Flow Analysis in Stock Selection

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply